immutep (asx:imm) - update on tacti-002 phase ii and insight-003 phase 1 data presented at sitc 2022
Published 1 year ago • 31 plays • Length 52:08Download video MP4
Download video MP3
Similar videos
-
47:53
immutep (asx:imm) tacti-003 results, june 2024
-
56:38
immutep (asx:imm) webcast for tacti-002 data presented at asco 2022
-
8:42
immutep (asx:imm) announces positive results in head and neck cancer treatment
-
50:13
immutep tacti-002 and insight global webcast slides
-
56:38
immutep (asx:imm, nasdaq:immp) webcast for tacti-002 data presented at asco 2022 - 10 jun 2022
-
1:12:13
immutep tacti-002 and insight clinical results & update
-
16:06
immutep (asx:imm) - webinar presentation
-
9:44
elementy magistrali sieci as-i
-
1:21:38
sccm pxe boot flow || master sccm pxe boot || pxe boot deep dive
-
47:53
immutep (asx:imm, nasdaq:immp) tacti-003 results, june 2024
-
16:07
immutep (asx:imm) - webinar presentation
-
46:43
immutep limited (asx:imm, nasdaq:immp) - webcast presentation for cohort b of tacti-003 trial
-
15:49
immutep (asx:imm) - webinar presentation
-
3:33
immutep (asx:imm) reports positive trial data
-
1:14:06
immutep (asx:imm) sitc 2021 results - management update
-
4:19
immutep (asx:imm) clinical trial update
-
7:17
immutep (asx:imm) delivering strong data in first-line non-small cell lung cancer
-
50:22
immutep (asx:imm) esmo congress results webinar, october 2023
-
4:44
immutep (asx:imm) - innovative cancer therapies
-
5:42
immutep (asx:imm) receives fast track designation from fda
-
6:03
immutep (asx:imm) reports positive discussions with the fda and strong survival data